secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001104659-24-075388
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO raises $12.5M in private placement; extends cash runway into Q4 2025
-----------------------------------------------------------------------------

- Gross proceeds of ~$12.5M from sale of 1,197,314 common shares at $5.85 and 9,393 Series H preferred shares at $585.00.
- Series H preferred convertible into 100 common shares each, subject to 9.99% beneficial ownership limitation.
- Cash runway extended into Q4 2025, including $9.1M remaining from CIRM award.
- Proceeds to fund clinical development of KPI-012 for persistent corneal epithelial defect.
- Private placement led by SR One with ADAR1 Capital and another investor; expected close June 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000110465924075388/0001104659-24-075388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000110465924075388/tm2418252d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-075388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer